Premiere Educational Resource for Human Nuclear Receptor Information State College, PA (12/8/2016) INDIGO Biosciences, Inc. is pleased to announce the relaunch of the Nuclear Receptor Resource website. The NRR is a premier educational resource for information on the 48 human nuclear receptors. The NRR website has undergone a major redesign to make the site easierRead More
INDIGO Biosciences and Bertin Pharma Sign European Distribution Agreement
Ready-to-Use Nuclear Receptor Assay kits for over 20 disease states, including Cardiovascular and Metabolic Disease, Cancer, and Inflammation State College, PA (November 15, 2016) INDIGO Biosciences, the recognized industry-leader in Nuclear Receptor research, and Bertin Pharma have announced the completion of a European distribution agreement. Over 40 product references for studying nuclear receptors are nowRead More
INDIGO Offers Expansion of Industry-Leading FXR Assay
Meets industry demand for increased pre-clinical predictability. State College, PA (August 9, 2016) INDIGO Biosciences, the recognized industry leader in Nuclear Receptor research, announced the addition of the Mouse Farnesoid X Receptor (mFXR) assay to their FXR portfolio. This addition both complements INDIGO’s industry-leading human FXR assay and meets the demand for an expansion ofRead More
INDIGO Biosciences Raises $500 Thousand in Series B Funding
A Combination of Private Equity and Public Funds Invested State College, PA (August 2, 2016)– INDIGO Biosciences announced the completion of a $500,000 Series B financing round on June 28, 2016. The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) and AGSM, a private equity investment firm from Pittsburgh, Pennsylvania led this round. INDIGO’S latest financing willRead More